The Clinical Core will support projects and cores in areas relevant to clinical research. The three major components to the core include clinical trials, the prostate cancer clinical research information system, and advocacy activities.
Specific Aim 1 : To design, execute, accrue to, or otherwise facilitate the conduct and timely completion of clinical trials relevant to SPORE projects or Cores. UW, UBC, and OHSU clinical investigators will participate in this aspect of the core. Clinical trials specific to projects include pre- and post-radiation biopsy (Project 2), neoadjuvant IMC-A12 (Project 4), and MAXTAP (Project 5) studies. Numerous SPORE related trials, including InterSPORE trials, are in progress or in planning.
Specific Aim 2 : To continue to develop and enhance Caisis, the prostate cancer clinical research information system. Development of clinic abstraction templates, biospecimen clinical annotation protocol, quality control and assurance procedures, patient consent and specimen acquisition processes, and specimen tracking are priorities.
Specific Aim 3 : To support and engage the SPORE Advocacy Committee in the activities of the SPORE as well as in their own mission as a group. Goals of the committee include: continued interaction with local support groups, involvement of minority members on the committee and in clinical trials, invitation of UBC and OHSU patients to join Advocacy Committee. In order to better understand and interact with the SPORE projects, each Advocate will focus on a single project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-09
Application #
8130555
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
9
Fiscal Year
2010
Total Cost
$168,834
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53
Viswanathan, Srinivas R; Ha, Gavin; Hoff, Andreas M et al. (2018) Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174:433-447.e19
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Plymate, Stephen R; Sharp, Adam; de Bono, Johann S (2018) Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. JAMA Oncol 4:1187-1188
Russo, Joshua W; Gao, Ce; Bhasin, Swati S et al. (2018) Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer. Cancer Res 78:6354-6362
Sowalsky, Adam G; Ye, Huihui; Bhasin, Manoj et al. (2018) Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations. Cancer Res 78:4716-4730
Zhu, Yezi; Sharp, Adam; Anderson, Courtney M et al. (2018) Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. Eur Urol 73:727-735

Showing the most recent 10 out of 400 publications